A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers
MoonSun Jung(Cancer Institute of New South Wales), Michelle J. Henderson(New South Wales Department of Health), Anna DeFazio(The University of Sydney), David D.L. Bowtell(The University of Melbourne), Joshy George(Jackson Laboratory), Amanda J. Russell(University of Minnesota), André Oberthuer, Michelle Haber(Cancer Clinic), Jamie I. Fletcher(Cancer Institute of New South Wales), Tao Liu(Cancer Clinic), Bing Liu(UNSW Sydney), Wendy B. London(Dana-Farber Cancer Institute), Pei Yan Liu(Cancer Institute of New South Wales), Murray D. Norris(Cancer Clinic)
Cited by 137
Related Papers
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k